



CODEN [USA]: IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.3873005>Available online at: <http://www.iajps.com>

Research Article

**MANAGEMENT OF ORAL ANTICOAGULATION THERAPY
AFTER GASTROINTESTINAL BLEEDING**Dr. Asifa Tehreem¹, Dr Tabassum Bashir², Dr. Feeha Nizami¹¹Allied Hospital, Faisalabad²Department of Paediatrics. Nawaz Sharif Medical College. Gujrat.**Article Received:** April 2020**Accepted:** May 2020**Published:** June 2020**Abstract:**

Management of patients on antithrombotics undergoing emergency or elective gastrointestinal (GI) endoscopy has become a common and important clinical challenge. The basic aim of the study is to explore and analyze the different management methods of oral anticoagulation therapy after gastrointestinal bleeding. This cross sectional study was conducted in Allied Hospital, Faisalabad during March 2019 to January 2020. This study was done basically by analyzing different management methods of oral anticoagulation therapies which were used after gastrointestinal bleeding. We collect both demographical data and collect the views of patients after GIT bleeding. Then we further analyze this data by using MS excel and find the different values. In critical patients who are actively bleeding with persistent or intermittent haemodynamic instability, coagulation factors should be administered even in the case of therapeutic ranges. If the patient is haemodynamically stable and/or responds sufficiently to resuscitation, it is advisable to simply observe the patient closely and defer endoscopy. We do not recommend bridging anticoagulation therapy in patients with low thromboembolic risk. Another issue is the timing of anticoagulant resumption in patients with clinically significant GI haemorrhage and no source of bleeding identified at endoscopy.

Corresponding author:**Dr. Asifa Tehreem,**
Allied Hospital, Faisalabad

QR code



Please cite this article in press Asifa Tehreem et al, **Management Of Oral Anticoagulation Therapy After Gastrointestinal Bleeding.**, Indo Am. J. P. Sci, 2020; 07(06).

INTRODUCTION:

Antithrombotic agents, which include antiplatelet agents and anticoagulants, are increasingly used in Asia. Management of patients on anti-thrombotic undergoing emergency or elective gastrointestinal (GI) endoscopy has become a common and important clinical challenge¹. While practice guidelines have been developed by GI and endoscopy societies in the USA, Europe and the UK, it was uncertain whether they should be fully adopted in the Asian Pacific region. In September 2015 the Asian Pacific Association of Gastroenterology (APAGE) and the Asian Pacific Society for Digestive Endoscopy (APSDE) appointed KS and FKLC to form an ad hoc working group to evaluate current practice guidelines on the management of patients on anti-thrombotic undergoing GI endoscopy².

The burden of oral anticoagulants has also been recently broadened by the introduction of new oral anticoagulants, also named direct oral anticoagulants (DOACs), which directly inhibit either thrombin or the activated coagulation factor X. DOACs have been approved in Europe as alternatives to VKAs for preventing strokes and embolic events in patients with non-valvular AF, for thrombo-prophylaxis after major orthopedic surgery and for the prevention/treatment of deep venous thrombosis and pulmonary embolism³. Another direct inhibitor of the activated coagulation factor X is currently under regulatory review in Europe. These agents, which are characterized by a predictable anticoagulant effect at fixed doses, overcome some of the VKAs pitfalls such as their narrow therapeutic window, the need for frequent monitoring and dose adjustments as well as the interaction with foods and/or other drugs⁴.

Acute GI bleeding in patients taking anticoagulants raises several difficulties related to the balance

between thrombotic risks, associated with drug discontinuation or reversal, and hemorrhagic risks⁵. Gastroenterologists who manage such patients have largely varying attitudes and an overall scarce knowledge of this topic as recently reported in a national Italian survey. This might be related to several factors, such as the paucity of studies addressing the issue of acute GI bleeding in anticoagulated patients and the absence of RCTs comparing different management strategies. Moreover, practice guidelines by GI professional societies only marginally address this topic as they mostly focus on the management of anticoagulants in patients undergoing elective procedures⁶.

Objectives of the study

The basic aim of the study is to explore and analyze the different management methods of oral anticoagulation therapy after gastrointestinal bleeding.


Methodology of the study

This cross-sectional study was conducted in Allied Hospital, Faisalabad during March 2019 to January 2020. The data was collected from both genders. We collect both demographical data and collect the views of patients after GIT bleeding. Then we further analyze this data by using MS excel and find the different values.

RESULTS:**Timing of endoscopy**

First of all we find the time of endoscopy because it depends either it takes less time or more time. Considering the recognized benefits of early endoscopy in acute upper GI bleeding, various authors have recommended that endoscopy should not be postponed to correct coagulopathy in patients with an international normalized ratio ≤ 2.5 . In patients with supra-therapeutic INR values, endoscopy should preferably be postponed until the coagulopathy is partially or completely reversed⁷.

Proposed management method



In critical patients who are actively bleeding with persistent or intermittent hemodynamic instability, coagulation factors should be administered even in the case of therapeutic INR ranges and 4F-PCC rather than FFP should be used. If the patient is hemodynamically stable and/or responds sufficiently to resuscitation, it is advisable to simply observe the patient closely and defer endoscopy for 12–24 h, thus allowing for drug clearance and normal hemostatic functions to resume. The theoretical advantage of this approach is that endoscopic therapy may be easier and safer to perform in a patient who is not fully anticoagulated⁸.

Conversely, for actively bleeding patients with persistent or intermittent hemodynamic instability, emergent endoscopy may be appropriate. In this case, the use of non-specific pro-hemostatic agents to accelerate anticoagulation reversal may be considered. Practice guidelines recommend the use of such reversal agents in patients with life-threatening bleeding but no reversal strategy for DOACs has yet been validated. In a recent survey among hematology specialists on current DOACs reversal practices, factor concentrates (activated PCCs and rFVIIa) were prescribed in 41% of dabigatran-associated bleedings⁹.

DISCUSSION:

To date, four DOACs including dabigatran, apixaban, rivaroxaban and edoxaban have been approved by the FDA and are available in many countries in the Asia. Unlike vitamin K antagonists, DOACs are direct inhibitors of factor thrombin (dabigatran) and factor Xa (apixaban, rivaroxaban, edoxaban). This new class of anticoagulants has a rapid onset (1–4 hours) and offset of action (about 24 hours). However, drug elimination is prolonged in patients with reduced renal clearance¹⁰. Dabigatran is mostly eliminated by the kidneys (~80%), edoxaban has 50% of the dose undergoing renal elimination, whereas rivaroxaban (~33%) and apixaban (~25%) are less affected by renal impairment. To date, there is limited information on the management of patients with MHV and GI bleeding. With respect to anticoagulation reversal,

ACC/AHA guidelines issued in 2008 raised some concerns on the safety of administering PCC due to potential thromboembolic complications, including valve thrombosis, as well as high-dose (5–10 mg) IV vitamin K due to potential “warfarin resistance”. Low-dose (1–2.5 mg) IV vitamin K combined with FFP was recommended in the case of major bleeding. However, there is no evidence that bleeders with or without MHV should be treated differently; accordingly, the updated ACC/AHA guidelines recommend PCC as a reasonable alternative to FFP when urgent reversal is required¹¹. With respect to VKAs resumption, MHV patients should be considered at high risk of thromboembolic complications. In particular, prolonged anticoagulation withdrawal is a major risk factor for prosthetic valve thrombosis, a serious complication associated with significant morbidity and mortality.

Hence, it might be advisable to resume VKAs early in the second week (ideally on day 7) considering heparin bridge therapy until INR reaches the therapeutic level. For MHV patients at highest thrombotic risk (mitral MHV, multiple MHVs, MHV with prior stroke or AF, and MVH implanted within 6 months) a potential role for heparin bridge therapy starting 72 h after endoscopy may be advocated, provided that the hemostasis is established and the risk of rebleeding is low¹².

CONCLUSION:

We do not recommend bridging anticoagulation therapy in patients with low thromboembolic risk. Another issue is the timing of anticoagulant resumption in patients with clinically significant GI haemorrhage and no source of bleeding identified at endoscopy. In these patients, the timing should be decided based on estimates of the individual risks of rebleeding and thrombosis.

Recommendations

1. We do not recommend platelet transfusion because it does not improve the clinical outcome of patients on antiplatelet agents.
2. We recommend early resumption of aspirin, preferably within 3–5 days after endoscopic haemostasis.

REFERENCES:

1. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. *Ann Intern Med* 2010;152:1–9.
2. Kukreja N, Onuma Y, Garcia-Garcia HM, et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. *JACC Cardiovasc Interv* 2009;2:534–41.
3. Lee VW, Chau TS, Chan AK, et al. Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in *Helicobacter pylori* eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. *J Clin Pharm Ther* 2010;35:343–50.
4. Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. *Am J Gastroenterol* 2007;102:290–6.
5. Cullen, M.W., Kim, S., Piccini, J.P. et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. *Circulation: Cardiovascular Quality and Outcomes*. 2013; 6: 461–469
6. Zekowitz, M.D., Bridgers, S.L., James, K.E. et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. *Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. New England Journal of Medicine*. 1992; 327: 1406–1412
7. Lip, G.Y. and Agnelli, G. Edoxaban: a focused review of its clinical pharmacology. *European Heart Journal*. 2014; 35: 1844–1855
8. Hylek, E.M., Evans-Molina, C., Shea, C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. *Circulation*. 2007; 115: 2689–2696
9. Abu Daya, H., Eloubeidi, M., Tamim, H. et al. Opposing effects of aspirin and anticoagulants on morbidity and mortality in patients with upper gastrointestinal bleeding. *Journal of Digestive Diseases*. 2014; 15: 283–292
10. Thomopoulos, K.C., Mimidis, K.P., Theocharis, G.J. et al. Acute upper gastrointestinal bleeding in patients on long term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. *World Journal of Gastroenterology*. 2005; 11: 1365–1368
11. Marmo, R., Koch, M., Cipolletta, L. et al. Predicting mortality in patients with in-hospital nonvariceal upper GI bleeding: a prospective, multicenter database study. *Gastrointestinal Endoscopy*. 2014; 79: 741–749
12. Veitch, A.M., Baglin, T.P., Gershlick, A.H. et al. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. *Gut*. 2008; 57: 1322–1329.